HomeInsightsPE

Welcure Drugs & Pharmaceuticals Ltd PE Ratio

Welcure Drugs & Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.0 Cr

Volume Transacted

(Dec 11, 2024)

stocks purchased

22.8 K

Stocks Traded

(Dec 11, 2024)

Last Updated on: Dec 11, 2024

Image

Welcure Drugs & Pharmaceuticals Ltd

NSE: WELCUREDRUGS

PE

75

Last updated on: Dec 11, 2024

Key Highlights

  • The P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd is 75 as of 11 Dec 15:30 PM .
  • The P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd changed from 37.6 on March 2021 to 0 on March 2024 . This represents a CAGR of -100.00% over 4 years.
  • The Latest Trading Price of Welcure Drugs & Pharmaceuticals Ltd is ₹ 9.75 as of 11 Dec 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.5. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd

No data available

Company Fundamentals for Welcure Drugs & Pharmaceuticals Ltd

No data available

Image

Welcure Drugs & Pharmaceuticals Ltd

NSE: WELCUREDRUGS

Share Price

₹ 9.75

0.88 (9.92%)

stock direction

Last updated on: Dec 11, 2024

Market Price of Welcure Drugs & Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Welcure Drugs & Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
11 Dec 20249.75
10 Dec 20248.87
09 Dec 20248.07
02 Dec 20248.07
25 Nov 20248.07
18 Nov 20248.07
11 Nov 20248.07
04 Nov 20247.69
28 Oct 20247.69
21 Oct 20247.69

SWOT Analysis Of Welcure Drugs & Pharmaceuticals Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Welcure Drugs & Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Welcure Drugs & Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Welcure Drugs & Pharmaceuticals Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Welcure Drugs & Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Welcure Drugs & Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Welcure Drugs & Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Welcure Drugs & Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Welcure Drugs & Pharmaceuticals Ltd

No data available

* All values are in %

About Welcure Drugs & Pharmaceuticals Ltd

  • Incorporated on 4 Jun.'92, Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain.
  • The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc. WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL).
  • The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes. Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations.
  • It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen.

Welcure Drugs & Pharmaceuticals Ltd News Hub

News

Welcure Drugs & Pharmaceuticals reports standalone net loss of Rs 0.35 crore in the June 2024 quarter

Net Loss of Welcure Drugs & Pharmaceuticals reported to Rs 0.35 crore in the quarter ended...

Read more

2024-08-14 00:00:00

News

Welcure Drugs & Pharmaceuticals to table results

Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

2024-08-09 00:00:00

News

Welcure Drugs & Pharmaceuticals to hold board meeting

Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

2024-08-30 00:00:00

News

Welcure Drugs & Pharmaceuticals to conduct AGM

Welcure Drugs & Pharmaceuticals announced that the Annual General Meeting (AGM) of the com...

Read more

2024-09-11 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Welcure Drugs & Pharmaceuticals Ltd

What is the current PE Ratio of Welcure Drugs & Pharmaceuticals Ltd?

The Current PE Ratio of Welcure Drugs & Pharmaceuticals Ltd is 75.0 as on 11 Dec 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 11 Dec 2024.

What was the PE Ratio of Welcure Drugs & Pharmaceuticals Ltd last year?

The PE Ratio of Welcure Drugs & Pharmaceuticals Ltd was 50.25 last year, now the PE ratio is 75.0, showing a year-on-year growth of 49.3%.

What does the PE Ratio of Welcure Drugs & Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Welcure Drugs & Pharmaceuticals Ltd is 75.0. This ratio indicates that investors are willing to pay 75.0 times the earnings per share for each share of Welcure Drugs & Pharmaceuticals Ltd.

What is the PE Ratio Growth of Welcure Drugs & Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Welcure Drugs & Pharmaceuticals Ltd grew by 49.3% whereas, the EPS ratio grew by -161.5.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions